Get started
Author

Suzanne I.S. Mosely

Observed name: Suzanne Mosely
Observed institution: Babraham Institute
OpenAlex ID: A5058809239
Rational Selection of Syngeneic Preclinical Tumor Models for Immunotherapeutic Drug Discovery
2016 · Suzanne I.S. Mosely, John E. Prime, et al. · Cancer Immunology Research · 415
Age-dependent axonal transport and locomotor changes and tau hypophosphorylation in a “P301L” tau knockin mouse
2011 · Jonathan Gilley, Anjan Seereeram, et al. · Neurobiology of Aging · 92
Abstract 2776: MEDI5752: A novel bispecific antibody that preferentially targets CTLA-4 on PD-1 expressing T-cells
2018 · Simon J. Dovedi, Yariv Mazor, et al. · Cancer Research · 16
Abstract 1082: Linking tumor microenvironment properties in murine syngeneic tumors with resistance to immune checkpoint inhibitors: Insights from a quantitative systems approach
2019 · Gabriel Helmlinger, Ivan Azarov, et al. · Cancer Research · 2
Data from Rational Selection of Syngeneic Preclinical Tumor Models for Immunotherapeutic Drug Discovery
2023 · Suzanne I.S. Mosely, John E. Prime, et al.
Supplementary Figures 1 through 5, Supplementary Tables 1 through 4, and Supplementary Methods from Rational Selection of Syngeneic Preclinical Tumor Models for Immunotherapeutic Drug Discovery
2023 · Suzanne I.S. Mosely, John E. Prime, et al.
Supplementary Dataset from Rational Selection of Syngeneic Preclinical Tumor Models for Immunotherapeutic Drug Discovery
2023 · Suzanne I.S. Mosely, John E. Prime, et al.
Supplementary Figures 1 through 5, Supplementary Tables 1 through 4, and Supplementary Methods from Rational Selection of Syngeneic Preclinical Tumor Models for Immunotherapeutic Drug Discovery
2023 · Suzanne I.S. Mosely, John E. Prime, et al.
Supplementary Dataset from Rational Selection of Syngeneic Preclinical Tumor Models for Immunotherapeutic Drug Discovery
2023 · Suzanne I.S. Mosely, John E. Prime, et al.
Data from Rational Selection of Syngeneic Preclinical Tumor Models for Immunotherapeutic Drug Discovery
2023 · Suzanne I.S. Mosely, John E. Prime, et al.
Abstract 1082: Linking tumor microenvironment properties in murine syngeneic tumors with resistance to immune checkpoint inhibitors: Insights from a quantitative systems approach
2019 · Gabriel Helmlinger, Ivan Azarov, et al. · Tumor Biology
Abstract 3765: An anti-CD137 antibody can show greater efficacy in syngeneic mouse tumor models when combined with other immuno-oncology (IO) therapies
2018 · Matthew J. Robinson, Ines Osma-Garcia, et al. · Cancer Research
Abstract 4186: Syngenomic fingerprint: the biomic characterization of the mouse syngeneic tumor models
2016 · John E. Prime, Suzanne Mosely, et al. · Cancer Research
Abstract 389: The dual mTOR inhibitor, AZD2014, and castration increase intra-tumoral immune cell infiltration and anti-tumour activity in a genetically engineered mouse model of prostate cancer
2016 · Chiranjeevi Sandi, Antonio Ramos-Montoya, et al. · Cancer Research
Works count: 14
Citation count: 525
H-index: 3
I10-index: 3
Year
Topic
Type